Clinical Experience using Osimertinib in Patients with Recurrent Malignant Gliomas Containing EGFR Alterations

• DOI: 10.26502/jcsct.5079114
• Publication Date: 2021-05-10T10:42:37Z
• Authors: Marin Abousaud; Naqeeb M Faroqui; Glenn Lesser; Roy E Strowd; Shakti H Ramkissoon; Madan Kwatra; Kristin S Houston; Fang-Chi Hsu; Annette Carter; Robin Petro; Alisha T DeTroye
• Keywords: Osimertinib

Background: EGFR alterations are commonly observed in malignant gliomas (MG). Osimertinib, an irreversible EGFR-tyrosine kinase inhibitor, effectively penetrates the blood brain barrier and achieves therapeutic concentrations tissue.